Omeros Co. (NASDAQ:OMER - Free Report) - Analysts at HC Wainwright issued their Q2 2025 earnings estimates for Omeros in a research report issued on Tuesday, June 10th. HC Wainwright analyst B. Folkes expects that the biopharmaceutical company will post earnings per share of ($0.39) for the quarter. HC Wainwright currently has a "Buy" rating and a $9.00 target price on the stock. The consensus estimate for Omeros' current full-year earnings is ($3.09) per share. HC Wainwright also issued estimates for Omeros' Q3 2025 earnings at ($0.37) EPS, Q4 2025 earnings at ($0.27) EPS and FY2026 earnings at ($1.14) EPS.
Other research analysts also recently issued reports about the company. D. Boral Capital reaffirmed a "buy" rating and issued a $36.00 price target on shares of Omeros in a research report on Tuesday, May 13th. Needham & Company LLC reaffirmed a "hold" rating on shares of Omeros in a research report on Friday, May 16th. Finally, Wall Street Zen cut shares of Omeros from a "hold" rating to a "sell" rating in a research note on Friday, June 6th. One investment analyst has rated the stock with a sell rating, two have given a hold rating, three have given a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat.com, the company has an average rating of "Moderate Buy" and a consensus price target of $18.00.
Check Out Our Latest Analysis on Omeros
Omeros Stock Performance
Shares of Omeros stock traded down $0.05 during trading on Wednesday, reaching $3.57. The company's stock had a trading volume of 394,273 shares, compared to its average volume of 775,587. Omeros has a one year low of $2.97 and a one year high of $13.60. The firm has a market cap of $209.18 million, a price-to-earnings ratio of -1.55 and a beta of 2.20. The business's fifty day moving average price is $5.23 and its 200-day moving average price is $7.85.
Omeros (NASDAQ:OMER - Get Free Report) last released its earnings results on Thursday, May 15th. The biopharmaceutical company reported ($0.65) earnings per share for the quarter, missing analysts' consensus estimates of ($0.60) by ($0.05).
Institutional Trading of Omeros
A number of hedge funds have recently modified their holdings of OMER. Truvestments Capital LLC increased its position in shares of Omeros by 116.5% during the fourth quarter. Truvestments Capital LLC now owns 3,102 shares of the biopharmaceutical company's stock valued at $31,000 after purchasing an additional 1,669 shares during the period. Tower Research Capital LLC TRC boosted its stake in Omeros by 79.0% during the fourth quarter. Tower Research Capital LLC TRC now owns 4,467 shares of the biopharmaceutical company's stock worth $44,000 after buying an additional 1,972 shares in the last quarter. Quantbot Technologies LP bought a new stake in Omeros in the 4th quarter valued at $46,000. Picton Mahoney Asset Management increased its holdings in Omeros by 692.5% in the 4th quarter. Picton Mahoney Asset Management now owns 5,040 shares of the biopharmaceutical company's stock valued at $50,000 after buying an additional 4,404 shares during the period. Finally, GAMMA Investing LLC raised its stake in shares of Omeros by 14,486.3% in the 1st quarter. GAMMA Investing LLC now owns 7,439 shares of the biopharmaceutical company's stock valued at $61,000 after buying an additional 7,388 shares in the last quarter. Institutional investors own 48.79% of the company's stock.
Omeros Company Profile
(
Get Free Report)
Omeros Corporation, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting immunologic diseases, including complement-mediated diseases, cancers, and addictive and compulsive disorders. The company's products under development include Narsoplimab (OMS721/MASP-2) that has completed pivotal trial for hematopoietic stem-cell transplant-associated thrombotic microangiopathy (TA-TMA); that is in Phase III clinical trial for the treatment of immunoglobulin A nephropathy (IgAN); and Phase II clinical trial to treat COVID-19.
Featured Articles
Before you consider Omeros, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Omeros wasn't on the list.
While Omeros currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Need to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
